Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes

被引：0
|
作者：
A. Hemeryck
C. De Vriendt
F. M. Belpaire
机构：
[1] Heymans Institute of Pharmacology,
[2] University of Gent Medical School,undefined
[3] 9000 Gent,undefined
[4] Belgium e-mail: frans.belpaire@rug.ac.be Tel.: +32-9-2403355; Fax: +32-9-2404988,undefined
来源：
European Journal of Clinical Pharmacology | 1999年 / 54卷
关键词：
Key words CYP2C9; SSRI; (S)-warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To investigate the in vitro potential of selective serotonin reuptake inhibitors (SSRIs) to inhibit two CYP2C9-catalysed reactions, tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxylation.
引用
收藏
页码：947 / 951
页数：4
相关论文
共 50 条
  • [41] Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9
    Otake, Y
    Walle, T
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (02) : 103 - 105
  • [42] Effects of Selective Serotonin Reuptake Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryo-Preserved Hepatocytes
    Volotinen, Marjo
    Korjamo, Timo
    Tolonen, Ari
    Turpeinen, Miia
    Pelkonen, Olavi
    Hakkola, Jukka
    Maenpaa, Jukka
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (04) : 302 - 309
  • [43] Comparison of CYP2C9, CYP2D6, and CYP3A4 inhibition using recombinant enzyme with fluorescent probes versus human liver microsomes with classical probes
    Pass, G
    Schulz-Utermoehl, T
    O'Connor, D
    Katsila, T
    Watt, AP
    DRUG METABOLISM REVIEWS, 2003, 35 : 52 - 52
  • [44] THE EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON CYTOCHROME-P4502D6 (CYP2D6) ACTIVITY IN HUMAN LIVER-MICROSOMES
    CREWE, HK
    LENNARD, MS
    TUCKER, GT
    WOODS, FR
    HADDOCK, RE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) : 262 - 265
  • [45] Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model
    Ramsden, Diane
    Perloff, Elke S.
    Whitcher-Johnstone, Andrea
    Ho, Thuy
    Patel, Reena
    Kozminski, Kirk D.
    Fullenwider, Cody L.
    Zhang, J. George
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (02) : 114 - 127
  • [46] Effect of fluvastatin on CYP2C9 activity using warfarin as a probe.
    Kim, M
    Nafziger, AN
    Kirchheiner, J
    Bauer, S
    Gaedigk, A
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P28 - P28
  • [47] Prediction of the oral clearance of tolbutamide in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data
    Almond, Lisa M.
    Rowland-Yeo, Karen
    Howgate, Eleanor M.
    Dickinson, Gemma L.
    Tucker, Geoff T.
    Rostami-Hodjegan, Amin
    DRUG METABOLISM REVIEWS, 2006, 38 : 209 - 210
  • [48] Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro
    Turpeinen, M
    Nieminen, R
    Juntunen, T
    Taavitsainen, P
    Raunio, H
    Pelkonen, O
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (06) : 626 - 631
  • [49] CYP2C9 inhibition: Impact of probe selection and pharmacogenetics on in vitro inhibition profiles
    Kumar, Vikas
    Wahlstrom, Jan L.
    Rock, Dan A.
    Warren, Chad J.
    Gorman, Lee A.
    Tracy, Timothy S.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (12) : 1966 - 1975
  • [50] Effect of Ginkgo on CYP2C9: In vitro and in vivo studies.
    Greenblatt, DJ
    von Moltke, LL
    Perloff, ES
    Luo, Y
    Harmatz, JS
    Bedir, E
    Khan, IA
    Goldman, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P48 - P48
12345